Many serum/plasma glycoproteins have been commercially applied for screening cancer, including prostate-specific antigen (PSA) in prostate cancer, cancer antigen 15-3 (CA15-3) in breast cancer, and cancer antigen 125 (CA-125) in ovarian cancer [4,7,8]. This evidence concerns the gene MUC16 and breast carcinoma.